d2644e613f

Novartis eyecare unit Alcon to set up new HQ in Geneva, Switzerland

pharmafile | September 11, 2018 | News story | Manufacturing and Production Alcon, Novartis, eye care, pharma 

Alcon, the eyecare unit of Novartis, is set to move to a new home next year, after its parent company revealed that the Swiss city of Geneva had been chosen as its new headquarters.

The location will be the second of two sites which will serve as the company’s global headquarters, alongside its regional office for Europe, Middle East and Africa which is already located in the city. The new site will host the firm’s senior corporate leadership, and promises “a modern office complex offering world-class services and amenities, including close proximity to the Geneva international airport”.    

The decision means it will relocate from its current longtime home in Texas following completion of the company’s proposed spin-off from Novartis next year, where it has dwelt since Alcon’s founding in 1945. While the company plans to employ around 700 at its new Swiss home, the US site will reportedly remain a major one.

“We are delighted to announce Geneva as the location of Alcon’s new global headquarters following the proposed spinoff from Novartis,” said David Endicott, Chief Executive Officer at Alcon. “For more than 40 years, Alcon has had a significant presence in Switzerland, which is known for its progressive business climate and innovation-friendly policies. Being headquartered in Geneva will help further increase Alcon’s global scale and reach to better serve our customers.”

Advertisement

Matt Fellows

Related Content

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

drug-trials

Novartis candidate for Sjögren’s disease presents positive results

Novartis has reported positive results from two phase 3 clinical trials – NEPTUNUS-1 and NEPTUNUS-2 …

Mosquito image

First malaria medicine for infants under 4.5kg receives approval

Coartem (artemether-lumefantrine) Baby, or Riamet, has been approved by Swissmedic as the first malaria medicine …

The Gateway to Local Adoption Series

Latest content